Cargando…

Incidence, Treatment, and Survival Patterns for Sacral Chordoma in the United States, 1974–2011

INTRODUCTION: Sacral chordomas represent one half of all chordomas, a rare neoplasm of notochordal remnants. Current NCCN guidelines recommend surgical resection with or without adjuvant radiotherapy or definitive radiation for unresectable cases. Recent advances in radiation for chordomas include c...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Esther, Koffer, Paul P., DiPetrillo, Thomas A., Kinsella, Timothy J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018685/
https://www.ncbi.nlm.nih.gov/pubmed/27672621
http://dx.doi.org/10.3389/fonc.2016.00203
_version_ 1782452956008808448
author Yu, Esther
Koffer, Paul P.
DiPetrillo, Thomas A.
Kinsella, Timothy J.
author_facet Yu, Esther
Koffer, Paul P.
DiPetrillo, Thomas A.
Kinsella, Timothy J.
author_sort Yu, Esther
collection PubMed
description INTRODUCTION: Sacral chordomas represent one half of all chordomas, a rare neoplasm of notochordal remnants. Current NCCN guidelines recommend surgical resection with or without adjuvant radiotherapy or definitive radiation for unresectable cases. Recent advances in radiation for chordomas include conformal photon and proton beam radiation. We investigated incidence, treatment, and survival outcomes to observe any trends in response to improvements in surgical and radiation techniques over a near 40-year time period. MATERIALS AND METHODS: Three hundred forty-five microscopically confirmed cases of sacral chordoma were identified between 1974 and 2011 from the surveillance, epidemiology, and end results program of the National Cancer Institute. Cases were divided into three cohorts by calendar year, 1974–1989, 1990–1999, and 2000–2011, as well as into two groups by age ≤65 versus >65 to investigate trends over time and age via Chi-square analysis. Kaplan–Meier analyses were performed to determine effects of treatment on survival. Multivariate Cox regression analysis was performed to determine predictors of overall survival (OS). RESULTS: Five-year OS for the entire cohort was 60.0%. OS correlated significantly with treatment modality, with 44% surviving at 5 years with no treatment, 52% with radiation alone, 82% surgery alone, and 78% surgery and radiation (p < 0.001). Age >65 was significantly associated with non-surgical management with radiation alone or no treatment (p < 0.001). Relatively, fewer patients received radiation between 2000 and 2011 compared to prior time periods (p = 0.03) versus surgery, for which rates which did not vary significantly over time (p = 0.55). However, 5-year OS was not significantly different by time period. Age group and treatment modality were predictive for OS on multivariate analysis (p < 0.001). CONCLUSION: Surgery remains an important component in the treatment of sacral chordomas in current practice. Fewer patients were treated with radiation more recently despite advances in photon and proton beam radiation. OS remains unchanged. Additional analyses of margin status, radiation modality, and local control in current practice are warranted.
format Online
Article
Text
id pubmed-5018685
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-50186852016-09-26 Incidence, Treatment, and Survival Patterns for Sacral Chordoma in the United States, 1974–2011 Yu, Esther Koffer, Paul P. DiPetrillo, Thomas A. Kinsella, Timothy J. Front Oncol Oncology INTRODUCTION: Sacral chordomas represent one half of all chordomas, a rare neoplasm of notochordal remnants. Current NCCN guidelines recommend surgical resection with or without adjuvant radiotherapy or definitive radiation for unresectable cases. Recent advances in radiation for chordomas include conformal photon and proton beam radiation. We investigated incidence, treatment, and survival outcomes to observe any trends in response to improvements in surgical and radiation techniques over a near 40-year time period. MATERIALS AND METHODS: Three hundred forty-five microscopically confirmed cases of sacral chordoma were identified between 1974 and 2011 from the surveillance, epidemiology, and end results program of the National Cancer Institute. Cases were divided into three cohorts by calendar year, 1974–1989, 1990–1999, and 2000–2011, as well as into two groups by age ≤65 versus >65 to investigate trends over time and age via Chi-square analysis. Kaplan–Meier analyses were performed to determine effects of treatment on survival. Multivariate Cox regression analysis was performed to determine predictors of overall survival (OS). RESULTS: Five-year OS for the entire cohort was 60.0%. OS correlated significantly with treatment modality, with 44% surviving at 5 years with no treatment, 52% with radiation alone, 82% surgery alone, and 78% surgery and radiation (p < 0.001). Age >65 was significantly associated with non-surgical management with radiation alone or no treatment (p < 0.001). Relatively, fewer patients received radiation between 2000 and 2011 compared to prior time periods (p = 0.03) versus surgery, for which rates which did not vary significantly over time (p = 0.55). However, 5-year OS was not significantly different by time period. Age group and treatment modality were predictive for OS on multivariate analysis (p < 0.001). CONCLUSION: Surgery remains an important component in the treatment of sacral chordomas in current practice. Fewer patients were treated with radiation more recently despite advances in photon and proton beam radiation. OS remains unchanged. Additional analyses of margin status, radiation modality, and local control in current practice are warranted. Frontiers Media S.A. 2016-09-12 /pmc/articles/PMC5018685/ /pubmed/27672621 http://dx.doi.org/10.3389/fonc.2016.00203 Text en Copyright © 2016 Yu, Koffer, DiPetrillo and Kinsella. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yu, Esther
Koffer, Paul P.
DiPetrillo, Thomas A.
Kinsella, Timothy J.
Incidence, Treatment, and Survival Patterns for Sacral Chordoma in the United States, 1974–2011
title Incidence, Treatment, and Survival Patterns for Sacral Chordoma in the United States, 1974–2011
title_full Incidence, Treatment, and Survival Patterns for Sacral Chordoma in the United States, 1974–2011
title_fullStr Incidence, Treatment, and Survival Patterns for Sacral Chordoma in the United States, 1974–2011
title_full_unstemmed Incidence, Treatment, and Survival Patterns for Sacral Chordoma in the United States, 1974–2011
title_short Incidence, Treatment, and Survival Patterns for Sacral Chordoma in the United States, 1974–2011
title_sort incidence, treatment, and survival patterns for sacral chordoma in the united states, 1974–2011
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018685/
https://www.ncbi.nlm.nih.gov/pubmed/27672621
http://dx.doi.org/10.3389/fonc.2016.00203
work_keys_str_mv AT yuesther incidencetreatmentandsurvivalpatternsforsacralchordomaintheunitedstates19742011
AT kofferpaulp incidencetreatmentandsurvivalpatternsforsacralchordomaintheunitedstates19742011
AT dipetrillothomasa incidencetreatmentandsurvivalpatternsforsacralchordomaintheunitedstates19742011
AT kinsellatimothyj incidencetreatmentandsurvivalpatternsforsacralchordomaintheunitedstates19742011